In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

被引：0
|
作者：
Fischer, J. [1 ]
Bouhana, K. [1 ]
Chicarelli, M. J. [1 ]
Dahlke, J. [1 ]
Fell, B. [1 ]
Fulton, J. [1 ]
Guarnieri, A. [1 ]
Haygood, L. [1 ]
Jalluri, R. [1 ]
Johnson, A. [1 ]
McLean, B. [1 ]
Max, M. [1 ]
Rieger, R. [1 ]
Robinson, J. [1 ]
Rodriguez, M. [1 ]
Sullivan, F. [1 ]
Wang, Y. [1 ]
Winski, S. [1 ]
Zhou, Y. [1 ]
机构：
[1] Cogent Biosci, Res Dev, Boulder, CO USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 46 条
  • [21] Discovery of novel HIV integrase inhibitors part 2: Selection and evaluation of an azabicyclic carbamoyl pyridone inhibitor as a pre-clinical candidate
    Akiyama, Toshiyuki
    Johns, Brian A.
    Taoda, Yoshiyuki
    Yoshida, Hiroshi
    Taishi, Teruhiko
    Kawasuji, Takashi
    Murai, Hitoshi
    Yoshinaga, Tomokazu
    Sato, Akihiko
    Fujiwara, Tamio
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [22] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Pierre, Fabrice
    Chua, Peter C.
    O'Brien, Sean E.
    Siddiqui-Jain, Adam
    Bourbon, Pauline
    Haddach, Mustapha
    Michaux, Jerome
    Nagasawa, Johnny
    Schwaebe, Michael K.
    Stefan, Eric
    Vialettes, Anne
    Whitten, Jeffrey P.
    Chen, Ta Kung
    Darjania, Levan
    Stansfield, Ryan
    Bliesath, Joshua
    Drygin, Denis
    Ho, Caroline
    Omori, May
    Proffitt, Chris
    Streiner, Nicole
    Rice, William G.
    Ryckman, David M.
    Anderes, Kenna
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 356 (1-2) : 37 - 43
  • [23] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Fabrice Pierre
    Peter C. Chua
    Sean E. O’Brien
    Adam Siddiqui-Jain
    Pauline Bourbon
    Mustapha Haddach
    Jerome Michaux
    Johnny Nagasawa
    Michael K. Schwaebe
    Eric Stefan
    Anne Vialettes
    Jeffrey P. Whitten
    Ta Kung Chen
    Levan Darjania
    Ryan Stansfield
    Joshua Bliesath
    Denis Drygin
    Caroline Ho
    May Omori
    Chris Proffitt
    Nicole Streiner
    William G. Rice
    David M. Ryckman
    Kenna Anderes
    Molecular and Cellular Biochemistry, 2011, 356 : 37 - 43
  • [24] Discovery of Novel 2,4,5-Trisubstituted Pyrimidine Derivatives as Potent and Selective FGFR Inhibitors against Gatekeeper Mutants for the Treatment of NSCLC
    Zhang, Jianxia
    Wang, Yi
    Wang, Mengying
    Wang, Peipei
    Yan, Hao
    Wang, Dalong
    Zheng, Jiahao
    Li, Bin
    Chen, Chaoyue
    Cao, Di
    Zheng, Xiaohui
    Li, Xiaokun
    Wang, Kun
    Liu, Zhiguo
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 5907 - 5925
  • [25] LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma:: Results of a pre-clinical evaluation in vitro and in vivo.
    Catley, L
    Weisberg, E
    Tai, YT
    Lin, B
    Mitsiades, N
    Hideshima, T
    LeBlanc, R
    Shringapure, R
    Burger, R
    Mitsiades, C
    Chauhan, D
    Schlossman, R
    Munshi, N
    Richardson, P
    Griffin, J
    Anderson, K
    BLOOD, 2002, 100 (11) : 106A - 106A
  • [26] Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with pre-clinical brain availability and broad spectrum potency against ALK-resistant mutations
    Johnson, Ted W.
    Bailey, Simon
    Burke, Benjamin J.
    Collins, Michael R.
    Cui, J. Jean
    Deal, Judy
    Deng, Ye-Li
    Gukasyan, Hovhannes
    He, Mingying
    Hoffman, Jacqui
    Hoffman, Robert L.
    Huang, Qinhua
    Kania, Robert S.
    Kath, John C.
    Le, Phuong T.
    McTigue, Michele
    Palmer, Cynthia L.
    Richardson, Paul F.
    Sach, Neal W.
    Shen, Hong
    Smith, Graham L.
    Srirangam, Jay
    Zhu, Huichun
    Zhu, Jinjiang
    Dinh, Dac
    Engstrom, Lars
    Hu, Wenyue
    Lam, Hieu
    Lam, Justine L.
    Li, Qiuhua
    Smeal, Tod
    Timofeevski, Sergei
    Lu, Melissa West
    Yamazaki, Shinji
    Zou, Helen Y.
    Edwards, Martin P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [27] Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma
    Zheng, Bing
    Mao, Jia-Hui
    Qian, Lin
    Zhu, Hua
    Gu, Dong-hua
    Pan, Xiao-dong
    Yi, Fang
    Ji, Dong-mei
    CANCER LETTERS, 2015, 357 (02) : 468 - 475
  • [28] The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
    A P Toner
    F McLaughlin
    F J Giles
    F J Sullivan
    E O'Connell
    L A Carleton
    L Breen
    G Dunne
    A M Gorman
    J D Lewis
    S A Glynn
    British Journal of Cancer, 2013, 109 : 2131 - 2141
  • [29] The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
    Toner, A. P.
    McLaughlin, F.
    Giles, F. J.
    Sullivan, F. J.
    O'Connell, E.
    Carleton, L. A.
    Breen, L.
    Dunne, G.
    Gorman, A. M.
    Lewis, J. D.
    Glynn, S. A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (08) : 2131 - 2141
  • [30] The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models.
    Gill, Sonja J.
    Macdonald, Ruth
    Pin, Carmen
    Collins, Rob
    Leonard, Emilyanne
    Maglennon, Gareth
    Pike, Andy
    Cotton, Peter
    Hawthorne, Glen
    Pugh, Jordan
    Sargeant, Rebecca
    Sutton, Daniel
    Atkinson, James
    Jones, Stewart
    Chinery, Sarah
    Anderton, Mark
    CANCER RESEARCH, 2021, 81 (13)
12345